Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients

BMC Anesthesiology

Table 2 Adjusted percentage relative change (95% CI), initial biomarker concentrations for selected baseline characteristics relative to absence of the characteristic

Biomarker	Antibiotic pretreatment	Steroid pretreatment	Age above study sample median	Male gender	Chronic renal failure	Chronic liver insufficiency^a
Biomarker	(n = 236)^a,b	(n = 22)^a,c	(n = 462)	(n = 544)	(n = 206)^a	(n = 22)^a
PCT	-5.5% (-9.6%, -1.5%), p = 0.01	-5.3% (-17.4%, 6.7%), p = 0.38	-0.5% (-4.2%, 3.2%), p = 0.78	-4.1% (-7.8%, -0.3%), p = 0.03	1.2% (-4.2%, 6.5%), p = 0.67	14.2% (2.1%, 26.4%), p = 0.02
CRP	1.3% (-3.0%, 5.6%), p = 0.55	-12.8% (-25.4%, -0.2%), p = 0.05	-10.7% (-14.6%, -6.9%), p < 0.01	-5.5% (-9.4%, -1.6%), p = 0.01	-0.6% (-6.3%, 5.0%), p = 0.83	6.2% (-6.6%, 19.0%), p = 0.34
WBC	-4.1% (-8.4%, 0.2%), p = 0.06	11.7% (-1.0%, 24.4%), p = 0.07	-1.3% (-5.2%, 2.7%), p = 0.52	-1.0% (-5.0%, 2.9%), p = 0.61	-3.6% (-9.3%, 2.0%), p = 0.21	13.0% (0.2%, 25.8%), p = 0.05
ProADM	-5.4% (-8.6%, -2.2%), p < 0.01	1.8% (-7.4%, 11.1%), p = 0.70	13.2% (10.2%, 16.1%), p < 0.01	-8.8% (-11.6%, -5.9%), p < 0.01	10.8% (6.6%, 14.8%), p < 0.01	10.4% (0.5%, 20.2%), p = 0.04)
Copeptin	-2.9% (-6.4%, -0.5%), p = 0.10	2.1% (-7.9%,12.1%), p = 0.68	12.1% (8.9%, 15.4%), p < 0.01	-0.1% (-3.1%, 3.3%), p = 0.96	6.3% (1.8%, 10.9%), p = 0.01	7.5% (-3.2%, 18.1%), p = 0.17)

CI, confidence interval; CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cells count; ProADM, proadrenomedullin.
Values for baseline factors associated with a statistically significant adjusted relative change in the initial biomarker level are in bold type.
^aAll data on comorbidities and pretreatments were based on patient report and medical chart review.
^bIncludes patients receiving at least one dose of antibiotics irrespective of agent, regimen, or administration route.
^c≥ 20 mg/d prednisolone equivalent.

ISSN: 1471-2253